Trophoblastic disease review for diagnosis and management a joint report from the international society for the study of trophoblastic disease, european organisation for the treatment of trophoblastic disease, and the gynecologic cancer intergroup

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S109-S116

  Mangili, Giorgia ^a   Lorusso, Domenica ^b   Brown, Jubilee ^c   Pfisterer, Jacobus ^d   Massuger, Leon ^e   Vaughan, Michelle ^f   Ngan, Hextan Y S ^g   Golfier, Francois ^h   Sekharan, Paradan K ⁱ   Charry, Rafael Cortés ^j   Poveda, Andres ^k   Kim, Jae Weon ^l   Xiang, Yang ^m   Berkowtiz, Ross ⁿ   Seckl, Michael J ^o  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Gynecologic Oncology Center Kiel   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ANZGOG NHMRC   (Australia)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ GOVERNMENT MEDICAL COLLEGE   (India)

^j HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^k INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^l Seoul National University Hospital   (South Korea)

^m PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Diagnosis; Gestational trophoblastic disease; Management; Review

Indexed keywords

CHORIONIC GONADOTROPIN;

CHORIOCARCINOMA; ECHOGRAPHY; FERTILITY; HUMAN; HYDATIDIFORM MOLE; MEDLINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR; TWIN PREGNANCY; FEMALE; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MEDICAL ONCOLOGY; SOCIETIES, MEDICAL; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS;

EID: 84988723098     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000294     Document Type: Review

References (30)

1. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717-729.
2. Cortes-Charry R, Figueira LM, Garcia-Barriola V, et al. Gestational trophoblastic neoplasia: clinical trends in 8 years at Hospital Universitario de Caracas. J Reprod Med. 2006;51:888-891.
3. Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med. 2009;360:1639-1645.
4. Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013;33:406-411.
5. Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-Term outcome of placental-site trophoblastic tumours: A retrospective observational study. Lancet. 2009;374:48-55.
6. Hoffner L, Surti U. The genetics of gestational trophoblastic disease: A rare complication of pregnancy. Cancer Genet. 2012;205:63-77.
7. Fisher RA, Lavery SA, Carby A, et al. What a difference an egg makes. Lancet. 2011;378:1974.
8. Mangili G, Garavaglia E, Cavoretto P, et al. Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years? Am J Obstet Gynecol. 2008;198:302.e1-e4.
9. Cole LA. HCG, its free subunits and its metabolites. Roles in pregnancy and trophoblastic disease. J Reprod Med. 1998;43:3-10.
10. Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi39-vi50.
11. Fu J, Fang F, Xie L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012;10:CD007289.
12. Deicas RE, Miller DS, Rademaker AW, et al. The role of contraception in the development of postmolar gestational trophoblastic tumor. Obstet Gynecol. 1991;78:221-226.
13. Sebire NJ, Foskett M, Paradinas FJ, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-Twin. Lancet. 2002;359:2165-2166.
14. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med. 2002;47:445-450.
15. Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83:175-177.
16. Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: A retrospective cohort study. Lancet. 2012;379:130-135.
17. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer. 2001;11:73-77.
18. van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-Agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol. 2006;24:52-58.
19. You B, Harvey R, Henin E, et al. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer. 2013;108:1810-1816.
20. Ngan HY, Chan FL, Au VW, et al. Clinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease. Gynecol Oncol. 1998;70:192-194.
21. Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2009:CD007102.
22. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study. J Clin Oncol. 2011;29:825-831.
23. Lurain JR, Elfstrand EP. Single-Agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol. 1995;172: 574-579.
24. Lybol C, Sweep FC, Harvey R, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125:576-579.
25. Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57:219-224.
26. Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18:854-859.
27. Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31:280-286.
28. Neubauer NL, Latif N, Kalakota K, et al. Brain metastasis in gestational trophoblastic neoplasia: An update. J Reprod Med. 2012;57:288-292.
29. Yang J, Xiang Y, Wan X, et al. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol. 2006;103:479-482.
30. Mapelli P, Mangili G, Picchio M, et al. Role of 18 F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging. 2013;40:505-513.